Clinical Trial: A Study of CC-97540 in Participants With Severe, Refractory Systemic Lupus Erythematosus (SLE)

Study Status: RECRUITING
Recruit Status: RECRUITING
Study Type: INTERVENTIONAL

Official Title: A Phase 1, Multicenter, Open-Label Study Of CC-97540 (BMS-986353), CD19-Targeted Nex-T Chimeric Antigen Receptor (CAR) T Cells, in Participants With Severe, Refractory Systemic Lupus Erythematosus (SL

Brief Summary: The purpose of this study is to establish the tolerability, preliminary efficacy, and pharmacokinetics of CC-97540 in participants with severe, refractory Systemic Lupus Erythematosus (SLE).

Detailed Summary:
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Current Primary Outcome:

Original Primary Outcome:

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company

Dates:
Date Received: May 11, 2023
Date Started: September 13, 2023
Date Completion: September 13, 2023
Last Updated: January 02, 2024
Last Verified: January 01, 2024